Drug-Resistant Gonorrhoea Is a Global Warning, Not a Distant Threat

Last updated: October 23, 2026

A surge in sexually transmitted infections in Europe should not be treated as a story confined to sexual behaviour or particular risk groups. It exposes a larger danger: drug-resistant bacteria are spreading through communities and moving across borders, while the medicines used to treat them are running out.

Gonorrhoea makes that danger especially visible. Resistant strains detected in Cambodia have since been found in France and Australia. Ceftriaxone is the only antibiotic still recommended for treating gonorrhoea, and resistance to even that option is increasing.

The concern extends beyond gonorrhoea. Drug resistance is no longer limited to hospitals. It now reaches outpatient care, cities and countries where surveillance is limited and health systems are already under pressure.

The hospital problem has escaped hospital wards

Antibiotic resistance is often presented as an intensive-care problem: a threat to patients in hospitals, where infections can spread between vulnerable people and where antibiotic use is intensive.

That picture is incomplete. Resistant bacteria do not remain inside hospitals, nor do they necessarily begin there. They circulate through communities, carried by people who are infected or unknowingly colonised. Some can spread through routine interactions or survive on surfaces long enough to travel with us.

Travel, migration, trade and densely populated cities make that movement easier. The significance is not that every bacterial strain travels freely. Gonorrhoea still spreads through sexual contact. The wider point is that the movement of people and bacteria allows resistance to cross borders faster than health systems can respond.

For Europe, the STI surge should therefore be read as an early warning rather than an isolated outbreak. Resistant infections acquired in one country can be carried into another, including places where surveillance is limited and the greatest burden of disease already falls.

Why gonorrhoea is the warning sign

There were 82 million new gonorrhoea cases worldwide in 2020, with the majority in low- and middle-income countries. As resistance erodes the effectiveness of antibiotics once used to control the disease, some infections are becoming extremely difficult to treat.

Gonorrhoea is not simply one example among many. It shows what happens when resistance reaches the last recommended medicine. Neisseria gonorrhoeae has developed resistance to the antibiotics used against it, leaving ceftriaxone as the final recommended option. A growing number of cases are now resistant even to that.

The pattern is not unique to sexually transmitted infections. A gene that makes bacteria resistant to last-resort antibiotics was first identified in the 1990s. It moved between countries and became established worldwide within little more than a decade.

That history matters because it shows how quickly resistance can become entrenched. For gonorrhoea, the consequences include fewer treatment choices and a greater burden on health systems that may struggle to detect resistant infections quickly. In low- and middle-income countries, where the need is greatest and surveillance more limited, those consequences can be more severe.

The burden is not being shared equally

Drug resistance does not affect every community equally. People who need new antibiotics, including those with resistant gonorrhoea, are the clear losers when commercial incentives fail to produce the medicines they require.

The traditional research and development model is designed around profitability. That has repeatedly left the most needed antibiotics underdeveloped, particularly for populations in low- and middle-income countries where expected returns are lowest. The result is a widening gap between the infections health systems need to treat and the drugs available to treat them.

This is not only a problem for patients with STIs. Drug-resistant infections such as MRSA can be acquired in ordinary environments and are becoming more common outside hospitals. They are especially dangerous for vulnerable groups, including cancer patients. Large studies among cancer patients receiving outpatient care have reported high rates of resistant infections, with pneumonia occurring more frequently and carrying a significant risk of death.

The institutional trade-off is stark: communities absorb the consequences of resistance while the commercial system waits for a more profitable product. Antibiotic stewardship can reduce inappropriate and unnecessary use, and infection control remains essential, but both measures alone cannot close the gap. Resistance is now outpacing antibiotic development; one in six bacterial infections is resistant to first-line antibiotics.

A new model is already showing a way forward

The development of zoliflodacin demonstrates why the traditional model is not sufficient. It is a first-in-class antibiotic for multidrug-resistant gonorrhoea and the first new treatment developed solely for this disease in decades.

What matters is not only the medicine, but how it was developed. Its not-for-profit model, led by the Global Antibiotic Research & Development Partnership and partners, was designed around an unmet need rather than the usual commercial calculation.

That distinction is crucial. Public and philanthropic models can direct scarce development capacity towards diseases where the clinical need is urgent but sales prospects are weak. For people facing resistant infections, and for health systems already under strain, a drug that never reaches development is an option they cannot use.

Decision checklist: what to watch next

• Geographic spread:** Track whether resistant gonorrhoea strains continue appearing in countries beyond those already affected. Movement between Cambodia, France and Australia shows that national boundaries do not contain the threat.
• Reliability of the last option:** Watch for evidence that resistance to ceftriaxone is becoming more common. Its status as the only recommended antibiotic leaves limited room for another treatment failure.
• The pressure on lower-resource systems:** Consider whether surveillance and healthcare capacity can identify resistant infections without adding further strain to already burdened services.
• Resistance outside hospitals:** Follow reports of resistant infections acquired in community and outpatient settings, particularly among vulnerable patients.
• Antibiotic development:** Judge new proposals by whether they prioritise resistant infections and whether their funding models can operate without conventional profit incentives.
• Stewardship and infection control:** Do not treat either measure as a complete solution. Both remain necessary, but neither replaces new antibiotics.

Why this should concern everyone

The rise of drug-resistant gonorrhoea matters far beyond the people who acquire it. It shows that resistance can spread through ordinary life, cross borders and settle where healthcare systems have the least capacity to respond. The commercial failure to develop urgently needed antibiotics makes that danger worse.

The appropriate response is neither complacency nor panic. It is sustained attention to prevention, diagnosis, antibiotic stewardship, infection control and alternative development models. Europe’s STI surge is a warning that the old assumption—that resistant infections remain inside hospitals—has already been overtaken by events.

Key takeaways

• Drug-resistant gonorrhoea has spread across borders, with resistant strains detected in Cambodia later found in France and Australia.
• Ceftriaxone is the only remaining recommended antibiotic, and resistance to it is increasing.
• The burden falls hardest on low- and middle-income countries, where need is greatest and surveillance is more limited.
• Antibiotic stewardship and infection control are necessary but insufficient because resistance is outpacing new drug development.
• Not-for-profit development models offer a way to prioritise antibiotics that conventional commercial incentives neglect.